Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM and Continuous Infusion of Beta-lactams in Bacteremia
NCT03108690Phase 4Withdrawn
- Start
- Oct 2017
- Primary completion
- Mar 2023
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
01
Overview
A Phase 4 trial of benzylpenicillin, ampicillin, dicloxacillin, piperacillin + tazobactam, cefuroxime in Bacteremia. Planned start Oct 2017; status: withdrawn.
02
Drugs
benzylpenicillinampicillindicloxacillinpiperacillin + tazobactamcefuroxime
03
Conditions
Bacteremia
Beyond the preview
Go deeper on NCT03108690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108690.